Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy and Safety of Capivasertib (AZD5363), a Potent, Oral Pan-AKT Inhibitor, in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (CAPITAL).

Clinical cancer research : an official journal of the American Association for Cancer Research·2025
Same author

SETD1B mutations confer apoptosis resistance and BCL2 independence in B cell lymphoma.

The Journal of experimental medicine·2024
Same author

<i>Erratum</i> to: Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation.

Haematologica·2024
Same author

A comparison of the prognostic performance of the Lugano 2014 and RECIL 2017 response criteria in patients with NHL from the phase III GOYA and GALLIUM trials.

EJHaem·2023
Same author

Enhanced clinical assessment of hematologic malignancies through routine paired tumor and normal sequencing.

Nature communications·2023
Same author

Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation.

Haematologica·2023
Same journal

Artificial intelligence-augmented robotic surgery in gynecologic oncology: intraoperative assistance and analytics.

Current opinion in oncology·2026
Same journal

Artificial intelligence in cervical cancer screening and triage: a role-stratified systematic review and bivariate meta-analysis.

Current opinion in oncology·2026
Same journal

Deep learning assisting the surgical management of gynecologic cancers.

Current opinion in oncology·2026
Same journal

Pain management in pancreatic cancer: time to change our strategy!

Current opinion in oncology·2026
Same journal

Systemic radionuclide treatments in gastro-entero-pancreatic neuroendocrine tumours.

Current opinion in oncology·2026
Same journal

5-Fluorouracil at seventy: still attractive but barely understood. A cautionary tale for drug development.

Current opinion in oncology·2026
See all related articles

Related Experiment Video

Updated: May 28, 2026

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

CD30-targeted antibody therapy.

Anas Younes1

  • 1Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA. ayounes@mdanderson.org

Current Opinion in Oncology
|October 12, 2011
PubMed
Summary
This summary is machine-generated.

Brentuximab vedotin shows significant promise for treating CD30+ cancers like Hodgkin lymphoma and anaplastic large cell lymphoma (ALCL). This antibody-drug conjugate offers potent single-agent activity in relapsed cases.

More Related Videos

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics (DCAF)
09:39

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics (DCAF)

Published on: September 17, 2019

Related Experiment Videos

Last Updated: May 28, 2026

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics (DCAF)
09:39

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics (DCAF)

Published on: September 17, 2019

Area of Science:

  • Oncology
  • Immunotherapy
  • Pharmacology

Background:

  • Therapeutic targeting of CD30+ cancers has historically involved naked and conjugated monoclonal antibodies.
  • Early trials with anti-CD30 antibodies yielded unsuccessful outcomes.
  • Development of antibody-drug conjugates represents a significant advancement in targeting CD30+ malignancies.

Purpose of the Study:

  • To review current knowledge on therapeutic strategies for CD30+ cancers.
  • To evaluate the efficacy of naked and conjugated monoclonal antibodies, including antibody-drug conjugates.

Main Methods:

  • Review of existing literature and clinical trial data on CD30-targeting antibodies.
  • Analysis of Phase II study results for brentuximab vedotin in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma (ALCL).
  • Assessment of regulatory recommendations for accelerated approval.

Main Results:

  • Brentuximab vedotin, an antibody-drug conjugate, demonstrated substantial progress after earlier trials' unsuccessful outcomes.
  • Phase II studies showed high single-agent response rates: 75% in relapsed Hodgkin lymphoma and 86% in systemic ALCL.
  • These results led to a recommendation for accelerated FDA approval.

Conclusions:

  • Brentuximab vedotin exhibits potent single-agent activity for treating relapsed Hodgkin lymphoma and ALCL.
  • Ongoing clinical trials are evaluating the incorporation of brentuximab vedotin into frontline treatment regimens.
  • This highlights a significant advancement in CD30-targeted cancer therapy.